Ayvakit®
(Avapritinib) CStone Pharm(HK)Holding Limited

Composition:

• Available as film-coated tablet containing 100 mg, 200 mg or 300 mg of avapritinib

Indication(s):

• As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.